PDS Bio (PDSB) unusual buy this afternoon of 1000 ITM February $12.50 calls for $4.40, a $330M Biotech developing cancer immunotherapies. PDSB has a low short float for a small Bio at 3%. PDSB has two Phase 2 data readouts due Q4 2021 or Q1 2022 for Chemo-radiation and one with Merck’s Keytruda for Head and Neck cancer while Phase 2/3 in solid tumors seen for Q1 2022. Cantor with an Overweight rating and $25 target in June seeing the pipeline underappreciated with promising data in oncology and infectious diseases.